Access Pharmaceuticals
Access Pharmaceuticals reports new initiatives in oncology, oncology support care
Published in Oncology Business Week, July 23rd, 2006
Having successfully divested non-oncology assets in 2005, the company is now focused on the development of its core oncology product programs which include ProLindac, an innovative polymer-platinum prodrug entering two phase II clinical trials, MuGard, a supportive care treatment of mucositis for patients undergoing radiation therapy and chemotherapy for cancer, and other early stage oncology compounds that utilize the company's unique drug delivery platforms. The company's restructuring efforts included a previously announced...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- ArQule
ArQule initiates phase II trial of ARQ 501 for pancreatic cancer - Biomira
Biomira retains Janney Montgomery Scott to explore pipeline development options - CuraGen
CuraGen and TopoTarget initiate Phase II clinical trial with PXD101 for mesothelioma - CuraGen
CuraGen initiates Phase I clinical trial with CR011-vcMMAE for metastatic melanoma - Decision Resources
Sales of Genentech/Roche/Chugai's Herceptin for breast cancer to triple by 2015, report says - EntreMed
EntreMed presents data demonstrating antiangiogenic activity of 2ME2 in rheumatoid arthritis - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
